demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small cell lung cancer (SCLC). Details of the study have been published in the ...

Medical treatment of the disease is usually with somatostatin analogs. An open, prospective, single-center study by Maiza et al. examined the long term (≤18 years) antihormonal and antitumor ...

Paltusotine, an oral SST2 agonist, offers advantages over injectable somatostatin analogs, achieving high IGF-1 control rates in pretreated patients. Positive Phase 2 data for Paltusotine in ...

Molecular imaging, including somatostatin receptor scintigraphy but more so PET with specific tracers, such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging and follow-up of therapy in ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for ...